ClinicalTrials.gg
RecruitingNCT02884284Updated Aug 31, 2016

Prospective and Retrospective Breast Cancer Database

An observational study in Breast Cancer, sponsored by Institut Claudius Regaud. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-31.

Sponsored by Institut Claudius Regaud · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Breast Neoplasms by Institut Claudius Regaud — 6 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut Claudius Regaud.

Started
2015
with 1 other
Observational
3 of 26
1 open now
Registered
10th of 26
by date

Among the 26 studies in Breast Neoplasms by Institut Claudius Regaud, this one is one of 2 that started in 2015, is one of 3 observational ones, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 26 studies in Breast Neoplasms by Institut Claudius Regaud are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Breast Neoplasms by Institut Claudius Regaud, or all of them as a file.
02

Study summary

In order to accelerate border crossing between basic research and clinical research in breast cancer, it is necessary to easily use clinical and biological data. That is the reason why it is very important to create a clinical, biological and pathologic beast cancer database, mainly prospective but also retrospective. All data are from patients treated in Toulouse Centre.

The scientific community will easily have access to clinical and biological informations through a centralized, structured database , leading to optimize patients with breast cancer treatment.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • database
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female patient with breast cancer of any stage

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patient
  • confirmed breast cancer of any stage
  • Affiliated to a social security system in france
  • Who signed the

Exclusion criteria

Exclusion Criteria:

  • Any psychiatric or medical condition that would make the patient unable to give a signed
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Otherclinical biological database collection
06

What researchers measure

Primary outcomes

  1. Database of patients with breast cancer

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Jan 2025 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2016
First posted
Aug 31, 2016
Start
Feb 2015
Primary completionEst.
Jan 2025
CompletionEst.
Dec 2025
Last update
Aug 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02884284
Responsible party
Sponsor
First posted
Aug 31, 2016
Start date
Feb 2015
Primary completion
Jan 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Aug 31, 2016

Study contacts

Florence DALENC, MD
Contact
dalenc.florence@iuct-oncopole.fr
5 31 15 51 22 ext. 33
Florence DALENC, MD
principal investigator · Institut claudius regaud Toulouse ONCOPOLE

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion